Welcome to our dedicated page for Adverum Biotech SEC filings (Ticker: ADVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage gene therapy companies like Adverum Biotechnologies generate filings packed with trial data, licensing details, and complex R&D costs—information critical to anyone tracking breakthrough AAV treatments. Yet locating cash-burn figures, dosing-cohort updates, or dilution risks across a 300-page 10-K can be challenging. That’s why investors searching for “Adverum Biotechnologies SEC filings explained simply� start here.
Our platform delivers every disclosure the moment it hits EDGAR. From the annual report 10-K simplified to each Adverum Biotechnologies insider trading Form 4 transactions notice, StockTitan’s AI pinpoints what matters: trial-readout timelines, liquidity runways, and therapy-specific risk factors. Need the latest Adverum Biotechnologies quarterly earnings report 10-Q filing? It’s presented with plain-language summaries and side-by-side trend charts. Curious about management incentives? Dive into the proxy statement executive compensation and see AI-highlighted R&D performance metrics. Material study results or partnership updates arrive via Adverum Biotechnologies 8-K material events explained, while real-time alerts track every Form 4 insider transactions move before key data drops.
Use cases span monitoring executive stock sales ahead of Phase 2 readouts, comparing quarter-over-quarter cash balances, and understanding dilution clauses inside recent shelf registrations. Whether you’re performing an Adverum Biotechnologies earnings report filing analysis or simply “understanding Adverum Biotechnologies SEC documents with AI,� our tools surface answers faster than manual review. All filings, all forms, always up to date—so you spend less time parsing biotech jargon and more time making informed decisions.
Adverum reported accelerating clinical investment alongside a sharply widening operating loss and constrained liquidity. The company recorded a net loss of $49.2 million for the quarter and $96.2 million for the six months, compared with $30.5 million and $57.6 million in the prior-year periods. Cash, cash equivalents and short-term investments totaled $44.4 million at June 30, 2025 and the company used $81.5 million of cash in operations in the six months. Management states available funds, including proceeds from an August 2025 private placement, are expected to fund operations into the fourth quarter of 2025 but are insufficient to provide twelve months of liquidity, which raises substantial doubt about the company’s ability to continue as a going concern.
On the clinical front, Adverum is advancing its lead program, Ixo-vec. The company initiated the ARTEMIS Phase 3 trial in February 2025 and plans a second Phase 3 trial (AQUARIUS) subject to funding. LUNA Phase 2 52-week topline results showed meaningful treatment-burden reductions (annualized anti-VEGF injection reductions of 88% at 6E10 and 92% at 2E11 with injection-free rates of 54% and 69%), and OPTIC long-term data show durable responses out to multi-year follow-up. The company holds several regulatory designations for Ixo-vec (FDA Fast Track and RMAT, EMA PRIME, MHRA Innovation Passport).
Adverum Biotechnologies reported that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1, and the cover page of the report is presented in Inline XBRL as Exhibit 104.
The filing explicitly states that the information in the report and the exhibit is not deemed "filed" under the Exchange Act and will not be incorporated by reference into other SEC filings. The 8-K itself does not include the underlying financial figures; the detailed results are contained in the furnished press release.
Adverum Biotechnologies (ADVM) Chief Operating Officer Peter Soparkar reported multiple stock option adjustments on June 17, 2025, following the company's March 21, 2024 reverse stock split (10:1 ratio). All existing stock options were repriced to $10.14 per share.
Key option modifications include:
- 40,000 shares from $68.80 to $10.14, expiring 10/29/2029 (fully vested)
- 4,074 shares from $157.50 to $10.14, expiring 02/19/2030 (fully vested)
- 45,000 shares from $19.90 to $10.14, expiring 02/11/2034 (subject to vesting schedule)
The transactions involve the cancellation of existing options and simultaneous issuance of replacement options with adjusted strike prices. Total affected shares across all grants amount to 197,048. Most options maintain their original vesting schedules, with various expiration dates ranging from 2029 to 2034. This adjustment appears aimed at realigning executive incentives following the reverse stock split.
Adverum Biotechnologies (ADVM) reports changes in stock option holdings for Chief Development Officer Setareh Seyedkazemi. Following a 1:10 reverse stock split effective March 21, 2024, the company has repriced and restructured several stock option grants.
Key option modifications include:
- 42,500 shares: Exercise price reduced from $17.30 to $10.14, expiring January 2032
- 8,500 shares: Exercise price reduced from $12.90 to $10.14, expiring March 2032
- 40,000 shares: Exercise price reduced from $19.90 to $10.14, expiring February 2034
The adjustments maintain original vesting schedules: 25% first-year cliff followed by monthly vesting for most grants, with one grant vesting monthly over two years from August 2023. These modifications appear aimed at maintaining incentive value following the reverse split, with all options repriced to $10.14 per share.
Linda M. Rubinstein, Chief Financial Officer of Adverum Biotechnologies (ADVM), reported modifications to stock options following the company's reverse stock split effective March 21, 2024. The reverse split combined every ten shares into one share, with corresponding adjustments to stock options.
Key transactions on June 17, 2025:
- Cancellation and replacement of 85,000 stock options originally granted on August 3, 2023, with exercise price adjusted from $21 to $10.14
- Cancellation and replacement of 35,000 stock options originally granted on February 12, 2024, with exercise price adjusted from $19.90 to $10.14
The vesting schedules remain unchanged: the first grant vests 25% after six months with monthly vesting thereafter until August 3, 2026, while the second grant vests 25% after one year with monthly vesting until February 12, 2028, subject to continued service.
Adverum Biotechnologies (ADVM) reported changes in stock option holdings for Chief Medical Officer Rabia Gurses Ozden on June 17, 2025. The transactions involved the amendment of existing stock options following the company's March 21, 2024 reverse stock split (10:1 ratio).
Key modifications include:
- Cancellation and replacement of 8,000 fully vested options originally granted March 17, 2022, with exercise price adjusted from $13.50 to $10.14
- Cancellation and replacement of 4,000 fully vested options originally granted June 9, 2023, with exercise price adjusted from $15.60 to $10.14
These amendments represent a repricing of executive stock options to align with current market conditions, maintaining the same number of shares (adjusted for the reverse split) but at a more favorable exercise price. The total holdings after transactions amount to 12,000 directly owned stock options.
Laurent Fischer, CEO, President and Director of Adverum Biotechnologies (NASDAQ: ADVM), reported significant modifications to stock options on June 17, 2025. The transactions involved the repricing of multiple stock option grants to a new exercise price of $10.14 per share.
Key details of the option modifications:
- Total of 564,418 options were repriced across 8 different grants
- Original exercise prices ranged from $10.90 to $237.00
- All options were converted to the new strike price of $10.14
- Various vesting schedules remain unchanged, with dates ranging from 2030 to 2034
This filing follows a 1-for-10 reverse stock split effective March 21, 2024, where all share counts and exercise prices were adjusted accordingly. The repricing appears aimed at maintaining executive incentives following stock price changes, with no change to the number of underlying shares or vesting terms.
Form 4 filing reveals that Szilard Kiss, Director at Adverum Biotechnologies (ADVM), was granted stock options on June 17, 2025. Key details:
- Received 10,450 stock options to purchase common stock at an exercise price of $2.32 per share
- Options will vest on the earlier of June 17, 2026 or the 2026 annual stockholder meeting
- Options expire on June 16, 2035
- Vesting is subject to continued service and includes accelerated vesting provision upon change of control
This grant appears to be part of the company's director compensation program. The filing was submitted by attorney-in-fact Aneta Fergson on June 20, 2025.
Adverum Biotechnologies (ADVM) director James Paul Scopa received a stock option grant on June 17, 2025. The key details of this Form 4 filing include:
- Granted 10,450 stock options to purchase common stock at an exercise price of $2.32 per share
- Options will vest on the earlier of June 17, 2026 or the 2026 annual stockholder meeting
- Options expire on June 16, 2035
- Vesting is subject to continued service and includes accelerated vesting provisions in case of a change of control
This grant appears to be part of the company's regular director compensation program. The filing was signed by Aneta Fergson as attorney-in-fact on June 20, 2025.
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
